Page 68 of 178: studies 671 to 680 of 1,775, newest first. Back to the ketamine for depression overview
Journal of the American Board of Family Medicine : JABFM 2025 Annie Huang, Jennifer L Fernandez Vasquez, Catherine A Yeager
If available in one's practice area, augmenting current medication therapy with esketamine results in greater rates of remission for treatment resistant depression as compared with quetiapine1.
Frontiers in Psychiatry 2025 Alexandre Fraichot, Sophie Favre, Hélène Richard-Lepouriel 1 citation
Intranasal Esketamine is an effective rapid-acting antidepressant currently used to treat treatment-resistant depression. Artificial intelligence is another emerging tool in medicine, but little is known about the effectiveness of combining these innovations in psychiatry. This case report presents the outcome of a 37-year-old patient who received intranasal Esketamine treatment (84 mg) and...
Frontiers in Psychiatry 2025 Miriam Olivola, Filippo Mazzoni, Barbara Tarantino et al. 7 citations
Treatment-Resistant Depression (TRD) remains a major challenge in the management of Major Depressive Disorder (MDD). Esketamine, the S-enantiomer of ketamine and a glutamatergic modulator, was approved by the FDA and EMA for TRD in 2019. Beyond its rapid antidepressant effects, esketamine may enhance neuroplasticity, facilitating the reconnection with emotional and cognitive processes,...
Ketamine 2025 Pouya Movahed Rad, Akihiro Takamiya
Depression is a debilitating psychiatric disorder. Electroconvulsive therapy (ECT) and ketamine are effective treatments for severe depression, but target populations may differ. Systematic reviews on the few available trials show higher remission rates with ECT than with ketamine. Nonetheless, ketamine’s rapid onset of action is comparable to ECT but with less cognitive adverse effects. This...
Ketamine 2025 Jose Eduardo Guimaraes Pereira, Carlos Darcy Alves Bersot, Thiago Ramos Grigio et al. 1 citation
Neuropathic pain (NP) is a frequently undertreated component of chronic pain, posing challenges due to its complexity. This has led to interest in N-methyl-D-aspartate receptor (NMDAR) antagonists like ketamine. NP is linked to maladaptive processes, such as NMDAR-related windup and sensitization. While results from ketamine trials on chronic NP have been inconsistent, perioperative use has...
Ketamine 2025 Carson Chrenek, Jennifer Swainson
Although both intranasal esketamine and intravenous ketamine have proven efficacy and tolerability in treatment-resistant depression (TRD), patient access to these treatments is often limited due to cost, availability, and/or monitoring requirements. This article is intended to provide a synthesis of the current literature with regard to the pharmacologic use of ketamine in TRD and describe its...
Imaging Neuroscience 2025 Brandon Taraku, Jason S Nomi, Artemis Zavaliangos-Petropulu et al.
Ketamine produces fast-acting antidepressant effects in treatment-resistant depression (TRD). Prior studies have shown altered functional dynamics between brain networks in major depression. We thus sought to determine whether functional brain network dynamics are modulated by ketamine therapy in TRD. Participants with TRD (n = 58, mean age = 40.7 years, female = 48.3%) completed resting-state...
Frontiers in Psychiatry 2025 Ahmad H Almadani, Ayedh H Alghamdi, Fahad B Alfahad et al.
Nasal esketamine has demonstrated efficacy in the management of treatment-resistant depression and psychiatric emergency due to major depression. This study investigates acceptance and awareness of esketamine as a depression treatment option, focusing on factors that influence patients' acceptance, including adherence to current medication regimens, regardless of prior esketamine exposure. This...
Frontiers in Pharmacology 2025 Haoning Guo, Liling Tang, Miaoquan He et al. 5 citations
Ketamine and esketamine have demonstrated rapid, short-term antidepressant effects in major depressive disorder (MDD), but their relative safety remains unclear. This review aims to update the evidence on the safety of two agents for MDD and indirectly compare their safety and tolerability. We systematically searched PubMed, PsycINFO, Embase, and Cochrane databases up to 1 May 2025. Eligible...
Frontiers in Psychiatry 2025 Leonard Marx, Zümrüt Duygu Sen, Lena Vera Danyeli et al.
Ketamine's antidepressant effects have been linked to its modulation of glutamatergic neurotransmission and synaptic plasticity. However, the precise roles of both glutamate (Glu) levels and brain-derived neurotrophic factor (BDNF) in this process remain incompletely understood. This study examined the relationship between ketamine-induced changes in Glu levels and peripheral BDNF levels using...